BTKi Therapy for CLL and MCL: ASCO 2022
New Evidence With BTK Inhibitor Therapy in CLL and MCL From ASCO 2022

Released: July 06, 2022

Expiration: July 05, 2023

Brad S. Kahl
Brad S. Kahl, MD
Anthony Mato
Anthony Mato, MD, MSCE

Activity

Progress
1
Course Completed

In this episode, Brad S. Kahl, MD, and Anthony Mato, MD, MSCE, discuss their choices of 3 recent important trials presented at ASCO 2022 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The discussion will include analyses of:

  • The SHINE trial evaluating the addition of ibrutinib to bendamustine/rituximab followed by rituximab maintenance in the first-line setting for older patients with MCL
  • 3-year follow-up analysis from the CAPTIVATE fixed-duration cohort of first-line ibrutinib plus venetoclax for CLL/small lymphocytic lymphoma
  • Phase I/II study of zilovertamab, an anti-ROR1 antibody, plus ibrutinib in MCL or CLL